HM Payson & Co’s ImmuCell ICCC Stock Holding History

HM Payson & Co’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.2K	Hold	4,000	–	–	﹤0.01%	753
2026 Q1	$25.3K	Hold	4,000	–	–	﹤0.01%	811
2025 Q4	$24.6K	Hold	4,000	–	–	﹤0.01%	805
2025 Q3	$25.9K	Hold	4,000	–	–	﹤0.01%	797
2025 Q2	$27.8K	Hold	4,000	–	–	﹤0.01%	744
2025 Q1	$19.2K	Hold	4,000	–	–	﹤0.01%	796
2024 Q4	$20.6K	Hold	4,000	–	–	﹤0.01%	768
2024 Q3	$14.5K	Sell	4,000 -2,000	-33%	-$7.78K	﹤0.01%	806
2024 Q2	$29.1K	Hold	6,000	–	–	﹤0.01%	692
2024 Q1	$31.8K	Hold	6,000	–	–	﹤0.01%	675
2023 Q4	$30.3K	Hold	6,000	–	–	﹤0.01%	674
2023 Q3	$31K	Sell	6,000 -6,130	-51%	-$31.1K	﹤0.01%	662
2023 Q2	$61.9K	Buy	12,130 +4,000	+49%	+$20.5K	﹤0.01%	548
2023 Q1	$41.9K	Hold	8,130	–	–	﹤0.01%	606
2022 Q4	$49.8K	Hold	8,130	–	–	﹤0.01%	551
2022 Q3	$61K	Hold	8,130	–	–	﹤0.01%	545
2022 Q2	$71K	Hold	8,130	–	–	﹤0.01%	524
2022 Q1	$78K	Hold	8,130	–	–	﹤0.01%	533
2021 Q4	$65K	Buy	8,130 +6,130	+307%	+$54.8K	﹤0.01%	569
2021 Q3	$18K	Hold	2,000	–	–	﹤0.01%	756
2021 Q2	$19K	Hold	2,000	–	–	﹤0.01%	742
2021 Q1	$19K	Sell	2,000 -18,500	-90%	-$174K	﹤0.01%	765
2020 Q4	$122K	Sell	20,500 -9,000	-31%	-$52.4K	﹤0.01%	453
2020 Q3	$160K	Hold	29,500	–	–	﹤0.01%	393
2020 Q2	$139K	Buy	29,500 +4,000	+16%	+$17.4K	﹤0.01%	393
2020 Q1	$97K	Hold	25,500	–	–	﹤0.01%	408
2019 Q4	$131K	Sell	25,500 -1,000	-4%	-$5.16K	﹤0.01%	440
2019 Q3	$147K	Sell	26,500 -2,000	-7%	-$11.7K	0.01%	429
2019 Q2	$185K	Sell	28,500 -23,000	-45%	-$146K	0.01%	409
2019 Q1	$327K	Buy	+51,500	New	+$368K	0.01%	218

Other funds holding ICCC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HM Payson & Co's ICCC Position: Q2 2026 in Review

HM Payson & Co held its ImmuCell (ICCC) position steady in Q2 2026 at 4,000 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #753.

HM Payson & Co first reported a position in ICCC in Q1 2019 and has held it in 30 quarters since. The position peaked at $327K in Q1 2019. 31 funds tracked by Wall St. Rank hold ICCC as of Q2 2026.

HM Payson & Co held 4,000 shares of ImmuCell worth $40.2K as of Q2 2026.
HM Payson & Co left its ImmuCell share count unchanged in Q2 2026.
ImmuCell made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #753 holding.
HM Payson & Co first reported a position in ImmuCell in Q1 2019 and has held it in 30 quarters since.
HM Payson & Co's ImmuCell position peaked at $327K in Q1 2019.
31 funds tracked by Wall St. Rank held ImmuCell as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.